September 18, 2025
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) —…
Pharmaceuticals, Biotechnology and Life Sciences
HilleVax Stockholders Received $1.95 Per Share in Cash Plus a Contingent Value RightEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) —…
PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical…
– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of…
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid…
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today…
WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that…
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans…
Secures Incentive Offer of up to US$255K to Establish Operations in IndianapolisTORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025…
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary…
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) — UTR Therapeutics Inc., a biotechnology company advancing a novel RNA Overwriting platform,…